|Study Description:||The goal of this clinical research study is to learn if ponatinib can help to |
control CML in accelerated phase. The safety of this drug will also be studied.
Ponatinib is designed to block the function of BCR-ABL, which is the abnormal
protein responsible for causing leukemia in certain cells.
Ponatinib may cause a blood clot to form in an artery or in a vein. Depending
on the location of the clot, this could cause a heart attack, a stroke, severe
damage to other tissue, or death. A blood clot may occur within 2 weeks after
you start taking the drug. About 25% (1 in 4) of patients taking the drug form
an abnormal clot. Blood clots can occur in patients that do not have other
known risk factors for forming clots. If you develop a blood clot, you will
need to stop taking ponatinib. In some cases, emergency surgery could be needed
to remove the clot and restore blood flow.